Reconstitution of TIMP-2 expression in SH-SY5Y neuroblastoma cells by 5-azacytidine is mediated transcriptionally by NF-Y through an inverted CCAAT site

Exp Cell Res. 2003 Jun 10;286(2):209-18. doi: 10.1016/s0014-4827(03)00072-7.

Abstract

Advanced stage neuroblastomas (NB) exhibit a tissue inhibitor of metalloproteinase (TIMP)-2/matrix metalloproteinase (MMP) imbalance, considered a prerequisite for MMP involvement in tumor progression in vivo. Human SH-SY5Y NB cells exhibit a similar TIMP-2/MMP imbalance that promotes in vitro invasive behavior that is inhibited by exogenous TIMP-2. The DNA methyltransferase inhibitor 5-azacytidine (5-AzaC) redresses this TIMP-2/MMP imbalance, reconstituting TIMP-2 expression, without effecting that of MMP-2, by stimulating TIMP-2 transcription and inhibiting in vitro invasivity of SH-SY5Y cells. 5-AzaC stimulated transcription from a nonmethylated TIMP-2 promoter reporter gene construct consistent with regulation of a TIMP-2 transactivator. Promoter deletion and point-mutation analysis localized this effect to an inverted CCAAT element at position -73. This element bound specific complexes containing NF-YA and NF-YB proteins in SH-SY5Y nuclear extracts, the binding of which was augmented by 5-AzaC in association with enhanced levels of NF-YB protein and the function of which was confirmed by inhibition using dominant-negative NF-YA. The data highlight a novel indirect methylation-mediated mechanism for regulating the TIMP/MMP equilibrium in NB cells, involving repression of TIMP-2 relative to MMP-2 expression, dependent upon suboptimal NF-Y transcription factor function, which can be reversed by methyltransferase inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Azacitidine / pharmacology
  • CCAAT-Binding Factor / drug effects
  • CCAAT-Binding Factor / genetics
  • CCAAT-Binding Factor / metabolism*
  • Child
  • DNA Methylation / drug effects
  • Gene Expression Regulation, Enzymologic / drug effects
  • Gene Expression Regulation, Enzymologic / genetics*
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics*
  • Genes, Regulator / drug effects
  • Genes, Regulator / genetics*
  • Humans
  • Methyltransferases / antagonists & inhibitors
  • Methyltransferases / metabolism
  • Mutation / drug effects
  • Mutation / genetics
  • Neuroblastoma / enzymology*
  • Neuroblastoma / genetics*
  • Promoter Regions, Genetic / drug effects
  • Promoter Regions, Genetic / genetics
  • Protein Binding / drug effects
  • Protein Binding / genetics
  • Repressor Proteins / drug effects
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism
  • Tissue Inhibitor of Metalloproteinase-2 / drug effects
  • Tissue Inhibitor of Metalloproteinase-2 / genetics
  • Tissue Inhibitor of Metalloproteinase-2 / metabolism*
  • Transcription, Genetic / drug effects
  • Transcription, Genetic / genetics
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • CCAAT-Binding Factor
  • Repressor Proteins
  • Tissue Inhibitor of Metalloproteinase-2
  • Methyltransferases
  • Azacitidine